Neuland Labs reports Q4FY26 Total Income of 788.7 Cr, EBITDA 319.4 Cr, and PAT 212.5 Cr.

Neuland Laboratories LimitedNEULANDLAB · Filed with the exchange

CEO highlights strong FY26, good business visibility, and ongoing investments in Peptide Manufacturing and a new R&D Centre, paving way for sustainable growth.

Read the original filing(PDF)

No comments yet. Be the first.

More from Neuland Laboratories Limited

All announcements

Investor Meet09-09-2026
Analysts/Institutional Investor Meet/Con. Call Updates
Important07-09-2026
Updates
Credit Ratings25-08-2026
Credit Rating
Others23-08-2026
Copy of Newspaper Publication
Important14-08-2026
Updates
Investor Meet10-08-2026
Analysts/Institutional Investor Meet/Con. Call Updates

Free

Track this company, and every filing it makes

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

Create a free account

No card needed. Takes about a minute.